Patent ID: 8067421
Filing Date: 2011-11-29
Classification: C07D

Abstract:
1. A crystalline form of imatinib mesylate characterised by data selected from the group consisting of: a powder XRD pattern with peaks at 6.0, 8.6, 11.4, 14.2 and 18.3±0.2 degrees two-theta; a powder XRD pattern having peaks at 6.0, 8.6, 10.2, 11.4 and 14.2±0.2 degrees two-theta; a powder XRD pattern having at least five peaks selected from the list consisting of 6.0, 8.6, 10.2, 11.4, 14.2, 17.8, 18.3, 21.6, 22.4, 23.6 and 24.8±0.2 degrees two-theta; a powder XRD pattern as depicted in FIG. 19 ; a solid-state 13 C NMR spectrum with signals at 159.9, 158.2 and 153.4±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 51.5, 49.8, and 45.0±0.1 ppm; a solid-state 13 C NMR spectrum as depicted in FIG. 20 ; and a solid-state 13 C NMR spectrum as depicted in FIG. 21 .